BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 1st Quarter - Report

EMERGEX VACCINES HOLDING LTD.

via THE CONAFAY GROUP, LLC

1st Quarter (Jan 1 - Mar 31) · 2022Posted Apr 18, 2022Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: EMERGEX VACCINES HOLDING LTD.
Description: Vaccine company
Location: United Kingdom

Registrant

Firm: THE CONAFAY GROUP, LLC
Description: Life Sciences Consulting Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medical/Disease Research/Clinical Labs
Infectious disease, influenza and respiratory disease research
LobbyistsJULIE P. PAWELCZYK · EVANGELINE SMITH

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

EMERGEX VACCINES HOLDING LTD. — Lobbying — Receipts Report